{"id":60565,"date":"2024-12-31T19:02:49","date_gmt":"2024-12-31T18:02:49","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/bone-growth-products-market-focused-insights-2024-2029-global-players-medtronic-johnson-johnson-stryker-and-zimmer-biomet-lead-through-acquisitions-collaborations-and-new-product-launches-rese\/"},"modified":"2024-12-31T19:02:49","modified_gmt":"2024-12-31T18:02:49","slug":"bone-growth-products-market-focused-insights-2024-2029-global-players-medtronic-johnson-johnson-stryker-and-zimmer-biomet-lead-through-acquisitions-collaborations-and-new-product-launches-rese","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/bone-growth-products-market-focused-insights-2024-2029-global-players-medtronic-johnson-johnson-stryker-and-zimmer-biomet-lead-through-acquisitions-collaborations-and-new-product-launches-rese\/","title":{"rendered":"Bone Growth Products Market Focused Insights 2024-2029: Global Players Medtronic, Johnson & Johnson, Stryker and Zimmer Biomet Lead through Acquisitions, Collaborations and New Product Launches – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Bone Growth Products Market – Focused Insights 2024-2029”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe Bone Growth Products Market was valued at USD 1.09 billion in 2023, and is expected to reach USD 1.35 billion by 2029, rising at a CAGR of 3.72%.<\/p>\n

\nThe global bone growth products market report includes exclusive data on 30 vendors. The market is highly competitive, with global players like Medtronic, Johnson & Johnson, Stryker, and Zimmer Biomet leading through acquisitions, collaborations, and new product launches.<\/p>\n

\nSmall and mid-sized companies increasingly enter the market, focusing on novel, cost-effective products. There is a growing emphasis on developing advanced bone healing therapies, such as pulsed electromagnetic field therapies, to address challenges in bone regeneration, especially for elderly and diabetic patients. Key players like Bioventus, Orthofix, and Terumo are enhancing their product portfolios with innovative solutions.<\/p>\n

\nThe Rise of Self-Powered Implantable Devices<\/strong><\/p>\n

\nInvasive bone growth stimulators are implantable devices that supply electrical energy to non-healing fractures or bone fusion sites, aiming to induce bone formation, stimulate growth, and promote healing. These devices, which use direct current delivered via an implanted lead, offer a consistent current to the fracture site, overcoming issues related to patient compliance seen in non-invasive systems. Invasive stimulators are particularly indicated for non-unions of the tibia, femur, and humerus and have proven effective for high-risk individuals undergoing lumbar or sacral fusion, including those with a history of fusion failure or conditions such as smoking, obesity, or diabetes. Bone, being a piezoelectric material, generates a small electrical charge under strain, which aids in healing. The growing advantages of these devices suggest increased adoption in developed countries, with ongoing research to enhance their market presence and efficacy.<\/p>\n

\nImpact of Bone Morphogenetic Proteins (BMPs) in Spinal Fusion and Bone Regeneration<\/strong><\/p>\n

\nBone morphogenetic proteins (BMPs), part of the transforming growth factor-beta (TGF-beta) family, have become a promising alternative to autologous bone grafts, especially in spinal fusion and bone regeneration. Approved by the FDA in 2002 for anterior lumbar fusion, BMPs aim to enhance bone healing with fewer complications than traditional grafting methods. They have shown high effectiveness, with fusion rates of 98% compared to 76% for iliac crest grafts (ICBGs), and are used in various spinal fusion techniques, including interbody, posterolateral, and circumferential fusion. BMPs are comparable to ICBGs in safety and efficacy and are expanding into off-label uses, such as posterior spinal fusion and cervical fusion. BMPs, alongside other biological factors like FGF, PDGF, and IGF, play a significant role in advancing bone regeneration. While autologous grafts remain the standard in orthopedic procedures, BMPs offer a well-researched, effective alternative.<\/p>\n

\nThe Rising Adoption of Biocompatible Synthetic Bone Grafts and Biologics<\/strong><\/p>\n

\nThe growing use of biocompatible synthetic bone grafts and biologics is a key driver of the bone growth products market. Synthetic grafts, made from materials like ceramics, polymers, and composites, mimic natural bone structure, providing scaffolds for new bone growth while reducing disease transmission and immune rejection risks associated with allografts and autografts. These grafts are especially in demand for spinal fusion surgeries and trauma cases. Biologics, such as bone morphogenetic proteins (BMPs) and platelet-rich plasma (PRP), enhance natural bone healing by promoting cellular activity and bone growth. BMPs induce bone formation, improving outcomes in complex fractures, while PRP accelerates healing. These innovations are transforming the treatment of bone injuries, offering more effective, efficient, and personalized solutions, driving market growth as healthcare providers seek safer, cost-effective options.<\/p>\n

\nKeeping Up with Rapid Technical Advancements<\/strong><\/p>\n

\nBone growth stimulators are expensive and often not covered by insurance, leading many to seek affordable alternatives like physiotherapy, Ayurveda, and chiropractic care, especially in developing countries with high out-of-pocket costs. Due to their cost-effectiveness, these alternatives are popular in regions like Japan, China, and India. Additionally, discomfort from bone stimulators and a shortage of orthopedic surgeons drive patients toward traditional treatments. Expanding awareness, improving treatment access, and increasing insurance coverage could boost the adoption of bone growth products in low- and middle-income areas.<\/p>\n

\nGEOGRAPHICAL ANALYSIS<\/strong><\/p>\n

\nNorth America accounted for the largest global bone growth products market share, followed by Europe. The U.S. remains a major revenue contributor in North America due to the high penetration of spinal fusion procedures and a considerable volume of spinal fusion and non-fusion surgeries. The increasing prevalence of orthopedic diseases, accidental injuries, and the aging population primarily drive the growth. The availability of advanced, safer, and minimally invasive surgical treatments and ongoing technological innovations further support market expansion.<\/p>\n

\nIn Europe, Germany, France, the UK, Italy, and Spain are the primary revenue contributors to the global bone growth products market. This region benefits from a well-established and sophisticated healthcare infrastructure, providing access to advanced medical services, including spinal fusion and non-fusion procedures. The market’s growth is driven by the increasing prevalence of bone disorders and the availability of reimbursement coverage for spinal fusion surgeries across many European countries.<\/p>\n

\nCOMPETITIVE LANDSCAPE<\/strong><\/p>\n

\nKey vendors<\/strong><\/p>\n